GI Dynamics Inc : GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Fourth Quarter 2013

GI Dynamics Press Release - January 21, 2014

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Fourth Quarter 2013

LEXINGTON, Massachusetts & SYDNEY, Australia - 21 January 2014 -GI Dynamics, Inc. (ASX: GID) will hold a conference call to discuss the Company's financial results for the fourth quarter ended December 31, 2013, and its business outlook. Stuart A. Randle, president and chief executive officer, will host the call with Robert Crane, chief financial officer, and Mark Twyman, chief commercial officer.

The Company will file its Appendix 4C with the ASX on Thursday, January 30, 2014 (Friday, January 31, 2014, AUS). The briefing call to discuss financial results and business updates will be held at 4:30 p.m. U.S. EST on Monday, February 3, 2014 (8:30 a.m. AEDT on Tuesday, February 4, 2014).

Accessing the Briefing Call via Webcast:

A live webcast of the call will be available on the Company's website at investor.gidynamics.com. The webcast can be directly accessed at: http://edge.media-server.com/m/p/m4pfbapr/lan/en

Accessing the Briefing Call via Telephone:

For those preferring to listen by telephone, please dial in five minutes prior to the start of the call and provide the passcode 36402358. Regional dial-in numbers are as follows:

• United States callers please dial toll-free 1 [phone]
• Australia callers please dial toll-free 1 (800) 507-265
• International callers please dial 1 [phone]

Replay archive:

The webcast will be archived for 30 days following the call on the Company's website at investor.gidynamics.com.

About GI Dynamics

GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.  GI Dynamics is conducting a pivotal clinical trial of EndoBarrierin the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements; and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including but not limited to risks associated with our dependency on our lead product, the EndoBarrier®, doctors' or market acceptance of our products (particularly given the limited data regarding long-term benefits of our products), our ability to effectively commercialize our products, competition, the availability and level of third party reimbursement, the outcome of our clinical trials, our ability to obtain regulatory approval for our products in our target markets, our ability to maintain and enforce intellectual property protection for our products, reliance on specialized suppliers for components of our products, our ability to manage growth including international operations and more general risks impacting the medical device or healthcare industry.

Investor Enquiries:	Media Enquiries:
United States Robert Crane, Chief Financial Officer [phone]	United States/Europe: Dan Budwick, Pure Communications Inc. [phone]
Australia David Allen or John Granger, Hawkesbury Partners Pty Limited [phone]	Australia: Haley Price, Buchan Consulting Group [phone]